MedTrace Logo

Texting Intervention to Sustain HIV Prevention in Women in High-drug-use Contexts

NCT02447484 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2021-09-29

No results posted yet for this study

Summary

The purpose of this study is to determine whether a program of regular, theory-based text messages that encourages the message recipient to continue practicing safer sex (i.e., using condoms with sex partners) is effective in maintaining positive behavior change in women who have completed a brief safer-sex training.

Conditions

  • HIV
  • Syphilis
  • Gonorrhea
  • Chlamydia

Interventions

BEHAVIORAL

Mujer Segura Siempre

Participants receive personalized text messages twice a day, five days per week. Messages are designed to encourage women to maintain positive behavioral changes they have made in response to the baseline safer-sex training that is delivered to all participants regardless of intervention assignment. Message content is based upon theoretical constructs of behavior-change maintenance as articulated by Voils et al. (Health Education \& Behavior, 2013). Personalization elements include participant's name, times of day when she prefers to receive messages, and specific motivators of behavior change she expressed in the baseline interview.

BEHAVIORAL

General Health Message Texts

Participants receive generic health-promotion text messages twice a day, five days per week.

Sponsors & Collaborators

Principal Investigators

  • Thomas L Patterson, PhD · University of California, San Diego

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-01
Primary Completion
2021-04-30
Completion
2021-08-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02447484 on ClinicalTrials.gov